Duchenne Muscular Dystrophy

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Endpoints
Sarepta Therapeutics
Genethon
Duchenne Muscular Dystrophy
gene therapy
China
Pluristem
Flag link:
PTC to launch DMD drug with still high price tag
PTC to launch DMD drug with still high price tag
BioPharma Dive
PTC Therapeutics
drug pricing
Duchenne Muscular Dystrophy
Emflaza
Flag link:
Payer snubs PTC's Emflaza, signaling pricing trouble ahead of launch
Payer snubs PTC's Emflaza, signaling pricing trouble ahead of launch
Fierce Pharma
PTC Therapeutics
Emflaza
drug launches
drug pricing
Duchenne Muscular Dystrophy
Flag link:
Trial restart approval brings back DMD hope for Akashi
Trial restart approval brings back DMD hope for Akashi
BioPharma Dive
Akashi Therapeutics
Duchenne Muscular Dystrophy
clinical trials
HT-100
Flag link:
After being spurned at the FDA, PTC buys a controversial Duchenne MD therapy from Marathon
After being spurned at the FDA, PTC buys a controversial Duchenne MD therapy from Marathon
Endpoints
FDA
PTC Therapeutics
Duchenne Muscular Dystrophy
Emflaza
Marathon Pharma
Flag link:
Payor Re-Evaluation On Exondys Positive For Sarepta
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
How the newest Duchenne biotechs are getting a boost from patient groups
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Flag link:
A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
Endpoints
Duchenne Muscular Dystrophy
R&D
CRISPR-Cas9
Exonics Therapeutics
Flag link:
Marathon halts launch of DMD drug as $89K price attracts congressional heat
Marathon halts launch of DMD drug as $89K price attracts congressional heat
Fierce Pharma
Marathon Pharma
Duchenne Muscular Dystrophy
drug pricing
Bernie Sanders
Emflaza
Flag link:
The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price
The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price
Endpoints
Marathon Pharma
R&D
Duchenne Muscular Dystrophy
Emflaza
Flag link:
Why Did That Drug Price Increase 6,000%? It's The Law
Why Did That Drug Price Increase 6,000%? It's The Law
Forbes
drug pricing
deflazacort
generics
Duchenne Muscular Dystrophy
Emflaza
Marathon Pharma
Flag link:
FDA approves Marathon Pharma's Duchenne muscular dystrophy drug
FDA approves Marathon Pharma's Duchenne muscular dystrophy drug
Marketwatch
FDA
Marathon Pharma
Duchenne Muscular Dystrophy
Emflaza
Flag link:
Sarepta May Have More Upside After Sales Data
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta eyes a different approach to Duchenne: gene therapy
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
Flag link:
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Will Insurers Pay For Sarepta’s DMD Drug?
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
Flag link:
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Endpoints
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
Flag link:
FDA emails show how upset some officials were over the Sarepta approval
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link: